Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

J App Pharm Sci. 2017; 7(10): 182-184


Complete Response to Pembrolizumab in a Patient with Malignant Peripheral Nerve Sheath Tumor: The First Case Reported

Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi.




Abstract

Pembrolizumab and procarbazine have been developed as anticancer agents. This study aimed to evaluate the efficacy of the combination of pembrolizumab plus procarbazine in a case with malignant peripheral nerve sheath tumor (MPNST( for the first time. A 48-year-old man referred to the Clinic of Oncology with complaints of constant abdominal pain for a week that the pathology diagnosis showed MPNST. The pathologist reported spindle cell sarcoma (probably dedifferentiated liposarcoma) with a significant PD-L1 expression-tumor proportion score (TPS): 90%. The patient was treated with six courses bi-weekly pembrolizumab combined with procarbazine that after this treatment, abdominopelvic CT scan showed that his lesions completely were resolved. In conclusion, the combination of pembrolizumab with procarbazine can be a new treatment in the patients with MPNST that in the future studies, the clinicians can check PD-L1 in these patients for better therapeutic aims.

Key words: Malignant peripheral nerve sheath tumor, pembrolizumab, procarbazine






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.